[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637100":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":29,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":20,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":20,"enrollmentInfo":43,"targetDuration":20,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":57,"whyStopped":20,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":20},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant TQB2450 + Anlotinib","EXPERIMENTAL","Neoadjuvant TQB2450 + Anlotinib Drug: TQB2450 (PD-L1 inhibitor) 1200 mg intravenously every 3 weeks Drug: Anlotinib 12 mg orally once daily (2 weeks on, 1 week off) Treatment duration: 2-4 cycles prior to surgery",[13],"Drug: TQB2450 + Anlotinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TQB2450 + Anlotinib","Drug: TQB2450 (PD-L1 inhibitor) 1200 mg intravenously every 3 weeks Drug: Anlotinib 12 mg orally once daily (2 weeks on, 1 week off) Treatment duration: 2-4 cycles prior to surgery",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"jiwei huang","CONTACT","86-13651682825","huangjiwie@renji.com",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[30,32],{"name":31,"class":6},"Huadong Hospital",{"name":33,"class":6},"Chinese PLA General Hospital","100637100","phase-2-neoadjuvant-pd-l1-inhibitor-plus-anlotinib-for-kidney-preservation-in-complex-renal-cell-carcinoma-100637100",false,"NCT07602101","Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma","Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* • Age ≥18 years\n\n  * ECOG performance status 0-2\n  * Histologically confirmed clear cell renal cell carcinoma\n  * Clinical stage cT2-T3aN0M0 (AJCC 8th edition)\n  * RENAL nephrometry score ≥10\n  * Tumor assessed as requiring radical nephrectomy or complex partial nephrectomy\n  * Adequate organ function\n  * Signed informed consent\n\nExclusion Criteria:\n\n* • Prior systemic therapy for RCC (including ICIs or TKIs)\n\n  * Non-clear cell histology or sarcomatoid\u002Frhabdoid differentiation \\>20%\n  * Active autoimmune disease requiring systemic therapy\n  * Active uncontrolled infection (HBV\u002FHCV\u002FHIV)\n  * Prior organ transplantation\n  * Uncontrolled cardiovascular or pulmonary disease\n  * Pregnancy or breastfeeding","ALL","18 Years",{"count":44,"type":45},33,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score ≥10) clear cell renal cell carcinoma (ccRCC).\n\nThe primary objective is to determine whether neoadjuvant therapy can increase the rate of successful nephron-sparing surgery.\n\nIn addition, this study incorporates a pre-specified translational research platform including circulating tumor DNA (ctDNA) methylation-based minimal residual disease (MRD) monitoring, tumor multi-omics profiling, and radiomics analysis. Artificial intelligence-based models will be developed to predict treatment response and surgical conversion, enabling precision neoadjuvant strategies.",[51],"Clear Cell Renal Cell Carcinoma",[51,53,54,55,56],"Neoadjuvant Therapy","PD-L1","Anlotinib","Nephron-Sparing Surgery","NOT_YET_RECRUITING","2026-05-15",{"date":60,"type":61},"2026-05-22","ACTUAL",{"date":63,"type":45},"2026-05-31",{"date":65,"type":45},"2028-12-31",{"name":5,"class":6}]